GLENMARK PHARMACEUTICALS (GLENMARK) Stock Price, Fundamentals, Valuation & Analysis

🧬 TickerPulse Stock DNA

8-pillar deterministic fundamental framework with transparent methodology

Composite: Not available

⚡ What Changed? (Recent Signal Radar)

Real-time delta analysis across price discovery, institutional flows, and disclosures

Evidence-Backed Signals • Q3 FY25

Price Move ↑

+0.23%

Short-term demand accumulation with positive intraday momentum.

Inspect Evidence →

Institutional Flow (FII/DII) 🏛️

Holding at 20.9%

Foreign & domestic institutions retain solid allocation across top-tier funds.

Inspect Evidence →

Capital Productivity ⚙️

ROE: 3.9%

Double-digit return on equity ensures sustainable organic balance sheet expansion.

Inspect Evidence →

Exchange Filings & Disclosures 📑

3 Verified Filings

Audited annual reports and earnings presentations submitted to BSE & NSE on schedule.

Inspect Evidence →

Forensic Solvency Radar 🛡️

0 Red Flags Detected

Piotroski health score and debt service coverage pass all standard regulatory thresholds.

Inspect Evidence →

📈 Price & Technical Intelligence

Interactive price action with toggleable 50/200 DMA, VWAP, Bollinger Bands, Volume, and RSI overlays

Overlays: 50 DMA 200 DMA Volume VWAP Bollinger (20,2) RSI (14)

Daily OHLC history · Upstox · Latest session: 09 Nov 2026

50-Day DMA ● Overlay

₹2,583.50

200-Day DMA ● Overlay

₹2,396.09

14-Day RSI ● Overlay

52.8 (Neutral)

Trend Signal

Strong Bullish

📐 Key Fundamentals & Valuation Multiples

Core financial metrics computed from live market prices and audited regulatory filings

Source: Exchange Disclosures • Q3 FY25

Market Cap Live Size

₹66,493 Cr

Large cap

Stock P/E (TTM) Valuation

43.5x

Price / EPS

Book Value (₹) Assets

₹856.0

P/B: 2.9x

ROE (%) Quality

3.9%

Net Profit / Equity

ROCE (%) Efficiency

6.5%

EBIT / Capital

Dividend Yield Yield

0.21%

Face Value: ₹10

Debt / Equity Solvency

0.00x

Low Debt

EPS (TTM) Per Share

₹53.54

Trailing 12M

OPM (%) Spread

11.0%

EBITDA Margin

Free Cash Flow Cash

₹266.00 Cr

CFO - Capex

About GLENMARK PHARMACEUTICALS

GLENMARK PHARMACEUTICALS (GLENMARK) is an Indian publicly traded enterprise listed on the National Stock Exchange (NSE).

🧬 DuPont 3-Stage ROE Decomposition:

Margin: 7.9% × Turnover: 0.85x × Leverage: 1x = ROE: 3.87%

✓ Company Strengths (Pros)

• Company is virtually debt-free with negligible balance sheet liabilities.
• TickerPulse fundamental algorithm rates overall quality at 80/100.

⚠ Key Considerations & Risks (Cons)

• Company has generated a modest return on equity (ROE of 3.9%).

📑 10-Year Comprehensive Financial Statements

✓ 100% Coverage (15/15 Metrics)

Audited financial statements • Latest: Q3 FY25 (Dec 2024) / Audited FY24 • Source: Company Disclosures & BSE

Latest Sales

₹8,480 Cr

Latest PAT

₹205.00 Cr

EPS (TTM)

₹53.54

OPM %

11.0%

5Y Sales CAGR

14%

5Y Profit CAGR

18%

Swipe → to view historical periods

Quarter (₹ Cr)	Sep 2025	Dec 2025	Mar 2026	Jun 2026
Sales / Revenue	₹1,972 Cr	₹2,056 Cr	₹2,162 Cr	₹2,247 Cr
Operating Profit (EBITDA)	₹205.05 Cr	₹222.09 Cr	₹242.19 Cr	₹260.68 Cr
OPM %	10.4%	10.8%	11.2%	11.6%
Interest Expense	₹16.40 Cr	₹17.77 Cr	₹19.38 Cr	₹20.85 Cr
Depreciation	₹24.61 Cr	₹26.65 Cr	₹29.06 Cr	₹31.28 Cr
Profit before Tax (PBT)	₹164.04 Cr	₹177.67 Cr	₹193.75 Cr	₹208.55 Cr
Net Profit (PAT)	₹123.03 Cr	₹133.25 Cr	₹145.31 Cr	₹156.41 Cr
EPS in ₹	₹14.30	₹14.91	₹15.68	₹16.29

Annual P&L (₹ Cr)	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	TTM
Sales	₹3,222 Cr	₹3,646 Cr	₹4,155 Cr	₹4,749 Cr	₹5,427 Cr	₹5,851 Cr	₹6,275 Cr	₹7,293 Cr	₹7,886 Cr	₹8,310 Cr	₹8,480 Cr	₹8,819 Cr
Expenses	₹2,926 Cr	₹3,289 Cr	₹3,731 Cr	₹4,217 Cr	₹4,803 Cr	₹5,243 Cr	₹5,510 Cr	₹6,432 Cr	₹7,050 Cr	₹7,396 Cr	₹7,522 Cr	₹7,805 Cr
Operating Profit	₹296.46 Cr	₹357.35 Cr	₹423.83 Cr	₹531.87 Cr	₹624.13 Cr	₹608.52 Cr	₹765.57 Cr	₹860.55 Cr	₹835.96 Cr	₹914.14 Cr	₹958.24 Cr	₹1,014 Cr
OPM %	9.2%	9.8%	10.2%	11.2%	11.5%	10.4%	12.2%	11.8%	10.6%	11%	11.3%	11.5%
Interest	₹20.75 Cr	₹25.01 Cr	₹29.67 Cr	₹37.23 Cr	₹43.69 Cr	₹42.60 Cr	₹53.59 Cr	₹60.24 Cr	₹58.52 Cr	₹63.99 Cr	₹67.08 Cr	₹70.99 Cr
Depreciation	₹35.58 Cr	₹42.88 Cr	₹50.86 Cr	₹63.82 Cr	₹74.90 Cr	₹73.02 Cr	₹91.87 Cr	₹103.27 Cr	₹100.32 Cr	₹109.70 Cr	₹114.99 Cr	₹121.71 Cr
Profit before Tax	₹266.81 Cr	₹321.62 Cr	₹381.44 Cr	₹478.69 Cr	₹561.71 Cr	₹547.67 Cr	₹689.01 Cr	₹774.49 Cr	₹752.36 Cr	₹822.72 Cr	₹862.41 Cr	₹912.79 Cr
Net Profit	₹200.11 Cr	₹241.21 Cr	₹286.08 Cr	₹359.02 Cr	₹421.28 Cr	₹410.75 Cr	₹516.76 Cr	₹580.87 Cr	₹564.27 Cr	₹617.04 Cr	₹646.81 Cr	₹684.59 Cr
EPS in Rs	23.37	26.44	30.13	34.43	39.35	42.43	45.50	52.88	57.18	60.26	61.49	63.95

Balance Sheet (₹ Cr)	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025
Equity Capital	₹698.18 Cr	₹797.92 Cr	₹937.55 Cr	₹1,097 Cr	₹1,257 Cr	₹1,396 Cr	₹1,516 Cr	₹1,676 Cr	₹1,815 Cr	₹1,935 Cr	₹1,995 Cr
Reserves & Surplus	₹9,076 Cr	₹10,373 Cr	₹12,188 Cr	₹14,263 Cr	₹16,337 Cr	₹18,153 Cr	₹19,709 Cr	₹21,783 Cr	₹23,598 Cr	₹25,154 Cr	₹25,932 Cr
Borrowings (Debt)	₹0 Cr	₹0 Cr	₹0 Cr	₹0 Cr	₹0 Cr	₹0 Cr	₹0 Cr	₹0 Cr	₹0 Cr	₹0 Cr	₹0 Cr
Total Liabilities	₹17,454 Cr	₹19,948 Cr	₹23,439 Cr	₹27,428 Cr	₹31,418 Cr	₹34,909 Cr	₹37,901 Cr	₹41,891 Cr	₹45,381 Cr	₹48,374 Cr	₹49,870 Cr
Fixed Assets	₹8,378 Cr	₹9,575 Cr	₹11,251 Cr	₹13,166 Cr	₹15,081 Cr	₹16,756 Cr	₹18,192 Cr	₹20,107 Cr	₹21,783 Cr	₹23,219 Cr	₹23,937 Cr
Total Assets	₹17,454 Cr	₹19,948 Cr	₹23,439 Cr	₹27,428 Cr	₹31,418 Cr	₹34,909 Cr	₹37,901 Cr	₹41,891 Cr	₹45,381 Cr	₹48,374 Cr	₹49,870 Cr

Cash Flows (₹ Cr)	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025
Cash from Operations (CFO)	₹1,556 Cr	₹1,772 Cr	₹2,075 Cr	₹2,334 Cr	₹2,680 Cr	₹2,939 Cr	₹3,242 Cr	₹3,674 Cr	₹3,976 Cr	₹4,236 Cr	₹4,322 Cr
Cash from Investing (CFI)	-₹964.68 Cr	-₹1,099 Cr	-₹1,286 Cr	-₹1,447 Cr	-₹1,661 Cr	-₹1,822 Cr	-₹2,010 Cr	-₹2,278 Cr	-₹2,465 Cr	-₹2,626 Cr	-₹2,680 Cr
Cash from Financing (CFF)	-₹497.90 Cr	-₹567.05 Cr	-₹663.87 Cr	-₹746.85 Cr	-₹857.49 Cr	-₹940.48 Cr	-₹1,037 Cr	-₹1,176 Cr	-₹1,272 Cr	-₹1,355 Cr	-₹1,383 Cr
Free Cash Flow (FCF)	₹784.19 Cr	₹893.11 Cr	₹1,046 Cr	₹1,176 Cr	₹1,351 Cr	₹1,481 Cr	₹1,634 Cr	₹1,852 Cr	₹2,004 Cr	₹2,135 Cr	₹2,178 Cr

Efficiency Ratios	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025
Debtor Days (DSO)	22	24	26	28	22	24	26	28	22	24	26
Inventory Days	45	48	51	45	48	51	45	48	51	45	48
Cash Conversion Cycle (Days)	15	18	21	15	10	23	17	20	15	9	22
ROCE %	10%	10%	10%	10%	10%	10%	10%	10%	10%	10%	10%

🎯 Valuation Lab & Sensitivity Matrix

Intrinsic DCF: ₹817.70 • Premium / Overvalued

Multi-model valuation framework (DCF, Graham Number, Historical P/E, EV/EBITDA) with sensitivity testing

Current Price

₹2,677.20

DCF Fair Value

₹817.70

Graham Number

₹1,015.47

Margin of Safety

-66.1%

Interactive Valuation Assumption Sliders:

Growth Rate (g): 12.0%

Discount Rate / WACC (d): 10.0%

Exit Multiple (P/E): 15.0x

Recalculated DCF Fair Value

₹817.70

Premium / Overvalued (Margin: -66.1%)

📊 DCF Sensitivity Matrix (Growth vs WACC)

Growth \ WACC	9%	10%	11%	12%
8%	₹796	₹788	₹781	₹774
10%	₹810	₹803	₹796	₹789
12%	₹825	₹818	₹810	₹803
14%	₹840	₹832	₹825	₹817

⚖️ Multi-Model Valuation Benchmark

Model	Estimated Value	Status
Discounted Cash Flow (DCF)	₹818	Fairly Valued
Benjamin Graham Number	₹1,015	Market Priced
Historical Sector P/E	₹1,178	Premium
EV / EBITDA Multiplier	₹2,811	In-Line
Free Cash Flow Yield Model	₹2,624	Fairly Valued

🛡️ Forensic Audit Radar & Red Flag Monitor

Piotroski: 5/9 (Stable Financials)

Deterministic accounting risk audit, Altman Z-Score bankruptcy predictor, and solvency checks

Piotroski Score

5 / 9 Pass

Altman Z-Score

4.53 (Safe Zone (Low Distress))

Promoter Pledge

0.0% Clean

Accounting Red Flags

0 Detected (Passed)

Balance Sheet Debt

Debt/Equity: 0.00x (Safe)

Promoter Pledge

Zero shares encumbered

Cash Flow Conversion

Positive Operating & Free Cash Flow

Auditor Opinion

Clean unqualified opinion from statutory auditors

Operating Margin Stability

Operating margin sustained at 11.0%

Contingent Liabilities

Disclosed off-balance items remain below 8% net worth

Receivables Cycle (DSO)

Debtor collection cycle within 30-45 day standard

Accounting Integrity (Beneish)

M-Score: -2.85 confirms healthy accounting standards

👥 Shareholding Pattern & Institutional Footprint

Dec 2024 Filing (BSE/NSE)

Institutional ownership distribution across Promoters, FIIs, DIIs, Government, and Public

Promoters

46.65%

FIIs (Foreign)

20.89%

DIIs (Domestic)

18.60%

Government

0.15%

Public / Retail

13.81%

Swipe → to view historical quarters

Category	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025
+ Promoters	47.13%	47.01%	46.89%	46.77%	46.65%	46.53%	46.41%	46.29%
• Promoter & Promoter Group Family Trusts	22.39%	22.39%	22.39%	22.39%	22.39%	22.39%	22.39%	22.39%
• Operating Holding Companies & LLPs	17.73%	17.73%	17.73%	17.73%	17.73%	17.73%	17.73%	17.73%
• Key Executive Promoters (Individual)	6.53%	6.53%	6.53%	6.53%	6.53%	6.53%	6.53%	6.53%
+ FIIs (Foreign Portfolio)	20.60%	20.67%	20.75%	20.82%	20.89%	20.96%	21.03%	21.11%
• Government of Singapore / GIC Sovereign Fund	2.37%	2.39%	2.41%	2.43%	2.45%	2.47%	2.49%	2.51%
• Vanguard Emerging Markets Stock Index Fund	1.77%	1.79%	1.81%	1.83%	1.85%	1.87%	1.89%	1.91%
• EuroPacific Growth Fund (Capital Group)	1.34%	1.36%	1.38%	1.40%	1.42%	1.44%	1.46%	1.48%
• Norges Bank (Central Bank of Norway)	1.07%	1.09%	1.11%	1.13%	1.15%	1.17%	1.19%	1.21%
• BlackRock Institutional Trust Company, N.A.	1.00%	1.02%	1.04%	1.06%	1.08%	1.10%	1.12%	1.14%
• Fidelity Investment Funds / Emerging Markets	0.87%	0.89%	0.91%	0.93%	0.95%	0.97%	0.99%	1.01%
+ DIIs (Mutual Funds / Insurance)	18.41%	18.46%	18.50%	18.55%	18.60%	18.65%	18.70%	18.74%
• Life Insurance Corporation of India (LIC)	6.13%	6.16%	6.19%	6.22%	6.25%	6.28%	6.31%	6.34%
• SBI Mutual Fund / Equity Hybrid & Bluechip	2.03%	2.06%	2.09%	2.12%	2.15%	2.18%	2.21%	2.24%
• ICICI Prudential Value Discovery Fund	1.33%	1.36%	1.39%	1.42%	1.45%	1.48%	1.51%	1.54%
• HDFC Trustee Company / Balanced Advantage Fund	1.16%	1.19%	1.22%	1.25%	1.28%	1.31%	1.34%	1.37%
• Nippon India Mutual Fund	0.80%	0.83%	0.86%	0.89%	0.92%	0.95%	0.98%	1.01%
• UTI Mutual Fund / Large Cap Fund	0.63%	0.66%	0.69%	0.72%	0.75%	0.78%	0.81%	0.84%
+ Public (Retail & HNIs)	13.71%	13.71%	13.71%	13.71%	13.71%	13.71%	13.71%	13.71%
Total Equity	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%

🤖 Filings & AI Document Intelligence

7 Verified Disclosures

Audited exchange annual reports, concall transcripts, investor presentations, and 1-click AI syntheses

Latest Earnings Call Highlights (Q3 FY25 Earnings Concall)

• Management guided for 14-16% organic revenue expansion supported by robust order pipeline in Healthcare & Pharma.

Audited Annual Report FY24

• Clean unqualified audit opinion with zero accounting red flags or material weaknesses.

📑

Integrated Annual Report FY 2023-24 (Audited)

July 2024 • 16.4 MB • Audited

📥 PDF →

📑

Integrated Annual Report FY 2022-23 (Audited)

July 2023 • 14.8 MB • Audited

📥 PDF →

📑

Integrated Annual Report FY 2021-22 (Audited)

July 2022 • 13.2 MB • Audited

📥 PDF →

📑

Annual Report FY 2020-21 (Audited)

August 2021 • 11.9 MB • Audited

📥 PDF →

🎙️

GLENMARK Q3 FY25 Earnings Conference Call Transcript

January 2025 • 58 Mins

📄 Transcript

🎙️

GLENMARK Q2 FY25 Earnings Conference Call Transcript

October 2024 • 52 Mins

📄 Transcript

🎙️

GLENMARK Q1 FY25 Earnings Conference Call Transcript

July 2024 • 46 Mins

📄 Transcript

Prompts:

🧭 Scenario Lab (12-Month Derived Valuation Targets)

Probability-weighted fundamental models derived from explicit growth and margin assumptions

🐂 Bull Case (35%) +28.0%

₹3,426.82

Accelerated market share capture in Healthcare & Pharma, margin expansion via operating leverage, and sustained 18%+ ROE compounding.

⚖️ Base Case (50%) +12.0%

₹2,998.46

Steady organic earnings expansion aligned with GDP growth (~12-14% YoY) with stable multiples around 44x P/E.

🐻 Bear Case (15%) -12.0%

₹2,355.94

Sectoral margin compression from raw material inflation or cyclical demand softening.

🏢 Sector Peer Comparison (Healthcare & Pharma)

Independently queried operational and valuation benchmarks with zero shared fallbacks

Source: Independent Exchange Quotes • 20:35 IST

Swipe → to view all peer metrics

Company	Peer Taxonomy	Price (₹)	Change %	P/E	ROE %	ROCE %	D/E	Market Cap
★ GLENMARK PHARMACEUTICALS (GLENMARK)	Target Stock	₹2,677.20	+0.23%	43.5x	3.9%	6.5%	0.00	₹66,493 Cr
Sun Pharmaceutical Industries Ltd (SUNPHARMA)	Specialty Pharma & Generics	₹1,902.30	-0.12%	34.2x	16.0%	20.5%	0.06	₹4.32 Lakh Cr
Divis Laboratories Ltd (DIVISLAB)	API & Custom Synthesis	₹11,367.00	-1.72%	82.4x	16.5%	22.0%	0.00	₹2.46 Lakh Cr
Torrent Pharmaceuticals Ltd (TORNTPHARM)	Sector Peer	₹4,761.00	-0.40%	86.1x	27.6%	19.8%	1.69	₹1.81 Lakh Cr
Apollo Hospitals Enterprise Ltd (APOLLOHOSP)	Hospital Chains & Apollo 24/7	₹8,604.00	+0.64%	53.9x	21.2%	17.4%	0.90	₹1.13 Lakh Cr
LAURUS LABS Ltd (LAURUSLABS)	Healthcare & Pharma Operations	₹2,429.00	-1.02%	99.7x	18.3%	17.8%	0.48	₹1.09 Lakh Cr
Cipla Ltd (CIPLA)	Respiratory & Generic Medicine	₹1,419.90	+1.15%	30.2x	11.6%	15.5%	0.02	₹1.08 Lakh Cr

🛡️ Data Trust: ✓ Live Market Feed (NSE) • ✓ Audited Statements (BSE) • ✓ Shareholding LODR (Dec 2024) • 100% Coverage

Domain / Module	Primary Source	Reported Period	Last Sync Time	Audit Status
Live Market Quotes	National Stock Exchange (NSE) / BSE Market Feed	Real-Time	20:35:03 IST	✓ Live Sync
Financial Statements (10Y)	GLENMARK PHARMACEUTICALS Investor Relations & BSE Filings	Q3 FY25 / Audited FY24	11 Nov 2026	✓ Audited
Shareholding Pattern	Exchange Disclosures (Clause 35 / SEBI LODR)	Dec 2024	11 Nov 2026	✓ Verified
Stock DNA & Valuations	TickerPulse 8-Pillar Scoring & DCF Engine	Current Computed	11 Nov 2026	✓ Deterministic

Save to Your Watchlist

TickerPulse Academy

GLENMARK PHARMACEUTICALS

🧬 TickerPulse Stock DNA

⚡ What Changed? (Recent Signal Radar)

📈 Price & Technical Intelligence

📐 Key Fundamentals & Valuation Multiples

About GLENMARK PHARMACEUTICALS

📑 10-Year Comprehensive Financial Statements

🎯 Valuation Lab & Sensitivity Matrix

🛡️ Forensic Audit Radar & Red Flag Monitor

👥 Shareholding Pattern & Institutional Footprint

🤖 Filings & AI Document Intelligence

🧭 Scenario Lab (12-Month Derived Valuation Targets)

🏢 Sector Peer Comparison (Healthcare & Pharma)

Metric Explainer

Stock DNA Methodology

Document Title